Intermediatebiotechnology
Cystic Fibrosis Genetics
Overview
Cystic fibrosis is the classic autosomal recessive disorder: mutations in CFTR (chromosome 7) disable the chloride channel, dehydrating airway mucus and causing lung infections, pancreatic insufficiency, and male infertility. DeltaF508 (70% of alleles) deletes one phenylalanine, misfolding the protein. Carrier frequency ~1/25 in Northern Europeans; newborn screening, modulators (Trikafta), and gene-therapy research define modern care.
Learning objectives
- Describe CFTR function and mutation effects
- Explain deltaF508
- Calculate carrier and recurrence risks
- Explain modulator therapies
CFTR: the chloride channel
CFTR is an ATP-gated chloride channel in airway, pancreatic, sweat-duct, and vas deferens epithelia. Loss of function -> dehydrated secretions: thick mucus plugs airways (chronic Pseudomonas infection), blocks pancreatic ducts (malnutrition), raises sweat chloride (diagnostic test).
CF is a channelopathy: one ion channel's failure cascades into multi-organ disease.
DeltaF508 and mutation classes
deltaF508 (c.1521_1523delCTT): loss of phenylalanine 508 -> protein misfolds, degraded by ER quality control (class II). ~2,000 CFTR variants in six classes: production (I), processing (II), gating (III), conductance (IV), quantity (V), stability (VI). Class guides modulator choice.
deltaF508's frequency reflects a founder effect in European populations.
Inheritance and population genetics
Autosomal recessive: carrier parents -> 25% affected, 50% carrier per pregnancy. q^2 = 1/2500 (N. European births) -> q = 1/50, carriers ~1/25. Carrier screening panels cover common variants; residual risk calculations follow negative screens.
CF carrier screening is routine in pregnancy care in high-frequency populations.
Treatment revolution
Airway clearance, enzymes, antibiotics historically. Ivacaftor (2012, gating mutations), then Trikafta (elexacaftor/tezacaftor/ivacaftor, 2019): correctors + potentiator rescue deltaF508, transforming prognosis for ~90% of patients. Gene therapy/editing aims at the rest.
Trikafta treats the protein defect itself: a template for other genetic diseases.
Key points
- CFTR chloride channel loss -> dehydrated secretions, multi-organ disease
- deltaF508: misfolding (class II), 70% of alleles
- AR: 25% recurrence; carriers ~1/25 (N. European)
- Trikafta (modulators) rescues most patients
Common misconceptions
✓ Truth: Carriers are asymptomatic (possibly slight salt loss); disease needs two mutant alleles.
✓ Truth: ~90% carry responsive variants; nonsense/minimal-function patients await gene therapy.
Practice questions
Q1. Cystic fibrosis is inherited as
- Autosomal dominant
- Autosomal recessive
- X-linked
- Mitochondrial
Two mutant CFTR alleles required; carriers healthy.
Q2. deltaF508 causes CFTR to
- Overactivate
- Misfold and be degraded
- Duplicate
- Move to nucleus
Class II processing mutation: ER quality control destroys it.
Q3. If q^2 = 1/2500, carrier frequency is about
- 1/2500
- 1/25
- 1/50
- 1/10
From q^2 = 1/2500, q = 1/50; carrier frequency = 2pq ≈ 2 × 1/50 = 1/25 in Northern Europeans.
Q4. Trikafta works by which mechanism?
- Editing DNA
- Correcting and potentiating mutant CFTR protein
- Replacing lungs
- Killing bacteria only
Small molecules rescue folding (correctors) and gating (potentiator).
Click a question to reveal the answer and explanation.
Frequently asked questions
Why the sweat test?
CFTR also reabsorbs sweat chloride: elevated sweat Cl- (>60 mmol/L) diagnoses CF physiologically.
What is CBAVD?
Congenital bilateral absence of the vas deferens: CFTR-related male infertility, often the mildest CFTR phenotype.
Why did deltaF508 become common?
Possible heterozygote advantage (cholera/typhoid resistance hypotheses) or founder effects: debated.